We are live on ! Find out more
SPC

Slate Path Capital Portfolio holdings

AUM $6.73B
1-Year Est. Return 95.97%
This Fund
S&P 500
This Quarter Est. Return
+26.61%
1 Year Est. Return
+95.97%
3 Year Est. Return
+272.8%
5 Year Est. Return
+330.15%
10 Year Est. Return
+4,591.92%
AUM
$1.86B
AUM Growth
+$346M
Cap. Flow
+$9.81M
Cap. Flow %
0.53%
Top 10 Hldgs %
81.62%
Holding
33
New
4
Increased
6
Reduced
3
Closed
6

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$145M
2
FCX icon
Freeport-McMoran
FCX
+$74.6M
3
EQT icon
EQT Corp
EQT
+$48.6M
4
MOS icon
The Mosaic Company
MOS
+$37.5M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.9M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$192M
2
GE icon
GE Aerospace
GE
+$92.5M
3
CHTR icon
Charter Communications
CHTR
+$40.5M
4
CYCN icon
Cyclerion Therapeutics
CYCN
+$10.7M
5
NYT icon
New York Times
NYT
+$4.81M

Sector Composition

Rank Sector Weight
1 Communication Services 38.95%
2 Materials 28.71%
3 Healthcare 16.76%
4 Industrials 7.2%
5 Energy 3.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNAP icon
1
Snap
SNAP
$7.96B
$237M 12.76%
14,505,000
+65,000
+0.5% +$957K
CHTR icon
2
Charter Communications
CHTR
$17.3B
$185M 9.96%
381,000
-88,000
-19% -$40.5M
B
3
Barrick Mining
B
$60.9B
$182M 9.81%
9,795,000
– –
BHC icon
4
Bausch Health
BHC
$1.75B
$167M 8.99%
+5,579,948
New +$145M
NYT icon
5
New York Times
NYT
$12.6B
$159M 8.54%
4,930,000
-155,000
-3% -$4.81M
Z icon
6
Zillow
Z
$7.78B
$134M 7.24%
2,925,000
– –
KEX icon
7
Kirby Corp
KEX
$7.01B
$134M 7.2%
1,493,000
+128,000
+9% +$10.6M
MOS icon
8
The Mosaic Company
MOS
$7.19B
$132M 7.13%
6,120,000
+1,890,000
+45% +$37.5M
ALNY icon
9
Alnylam Pharmaceuticals
ALNY
$38.3B
$93.9M 5.06%
815,000
+200,000
+33% +$19.9M
FCX icon
10
Freeport-McMoran
FCX
$86.2B
$91.6M 4.93%
6,980,000
+6,795,000
+3,673% +$74.6M
PAAS icon
11
Pan American Silver
PAAS
$17.9B
$85.3M 4.59%
3,600,000
– –
MDCO
12
DELISTED
Medicines Co
MDCO
$69.5M 3.74%
818,042
-2,876,958
-78% -$192M
EQT icon
13
EQT Corp
EQT
$32.9B
$54.2M 2.92%
+4,970,000
New +$48.6M
SBSW icon
14
Sibanye-Stillwater
SBSW
$6.05B
$39.1M 2.1%
3,935,000
+1,438,747
+58% +$11.1M
RETA
15
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$24.5M 1.32%
120,000
– –
EEM icon
16
CALL
iShares MSCI Emerging Markets ETF
EEM
$27.5B
$14.9M 0.8%
333,000
– –
CUE icon
17
Cue Biopharma
CUE
$118M
$14.1M 0.76%
29,667
– –
QURE icon
18
uniQure
QURE
$2.75B
$10M 0.54%
+140,000
New +$7.69M
ZG icon
19
Zillow
ZG
$7.85B
$8.46M 0.46%
185,000
– –
I
20
DELISTED
INTELSAT S. A.
I
$7.73M 0.42%
1,100,000
– –
LX
21
LexinFintech Holdings
LX
$246M
$3.13M 0.17%
225,000
– –
TDW icon
22
Tidewater
TDW
$3.63B
$2.12M 0.11%
110,000
– –
APRN
23
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
$2.11M 0.11%
26,667
– –
AG icon
24
First Majestic Silver
AG
$7.52B
$2.08M 0.11%
170,000
– –
SNAP icon
25
CALL
Snap
SNAP
$7.96B
$1.8M 0.1%
110,000
– –
1
2

Similar funds

SPS
Susquehanna Portfolio Strategies Bala Cynwyd, Pennsylvania $6.73B AUM 45.57% 1-Year Est. Return
BHM
Briar Hall Management Nashville, Tennessee $6.72B AUM 4.95% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
CIMLRA
CBRE Investment Management Listed Real Assets Radnor, Pennsylvania $6.75B AUM 8.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return
JCAM
Jericho Capital Asset Management New York $6.76B AUM 88.1% 1-Year Est. Return
MSE
MUFG Securities EMEA London, United Kingdom $6.7B AUM 32.3% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

Slate Path Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Slate Path Capital held 33 positions worth $1.86B, up 23% from $1.51B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Slate Path Capital's Q4 2019 filing shows 4 new, 6 increased, 3 reduced and 6 closed positions. Its largest new stake was Bausch Health: 5,579,948 shares worth $167M. The largest sale was Medicines Co, an estimated $192M.

By sector, the portfolio is most concentrated in Communication Services at 39% of assets, down from 44% a quarter earlier, followed by Materials and Healthcare.

  • Slate Path Capital's largest Q4 2019 buy was Bausch Health: 5,579,948 shares worth $167M.
  • Slate Path Capital added most to Freeport-McMoran in Q4 2019, an estimated $74.6M increase.
  • Slate Path Capital's biggest Q4 2019 reduction was Medicines Co, cutting an estimated $192M.
  • Slate Path Capital fully exited GE Aerospace in Q4 2019, selling an estimated $92.5M.
  • Slate Path Capital's ten largest holdings make up 82% of its $1.86B portfolio in Q4 2019.
  • Slate Path Capital opened 4 new positions and closed 6 in Q4 2019.
  • Slate Path Capital's portfolio value rose 23% quarter-over-quarter to $1.86B.

Based on Slate Path Capital's 13F filing for Q4 2019, filed 14 Feb 2020.